NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2007.00 2.60 (0.13%)

461.5K NSE+BSE Volume

NSE 23 Sep, 2025 3:54 PM (IST)

91,670.6

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

US FDA Observation

Lupin's Pune biotech facility receives Form 483 with four observations from the US FDA See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Search Inside the pdf :

Lupin Ltd.

21 Aug 2025

2007.00

0.13%

Braving sector headwinds

Buy: Lupin Ltd.

Sharekhan

A shift to complex drugs in recent times in the US led to revenue and PAT CAGRs of 21.93% and 64.18% over FY22 to FY25.

Lupin Ltd. is trading above its 150 day SMA of 1980.4

Lupin Ltd.

07 Aug 2025

2007.00

0.13%

Another quarter, another earnings beat

Buy: Lupin Ltd.

Target

Emkay

Lupin delivered yet another quarter of earnings outperformance vs street as well as our estimates, with the beat in 1QFY26 being driven by a higher gross margin.

Lupin Ltd. is trading above its 150 day SMA of 1980.4

Lupin Ltd.

07 Aug 2025

2007.00

0.13%

Lupin (LPC IN) Q1FY26 Result Update Multiple growth...

Buy: Lupin Ltd.

Prabhudas Lilladhar

Lupin's (LPC) Q1FY26 EBITDA stood at Rs16.4bn (up 28% YoY) was in line with our estimates on the back of higher US sales supported by niche launches (gTolvaptan). LPC saw remarkable turnaround in profitability with ~2x jump in EBITDA over FY23-24 aided by better product mix, continued niche launches in the US, clearance from USFDA for facilities, domestic formulations regaining momentum and cost optimization measures. We expect margins to sustain given a strong pipeline in the US. Our FY26E and FY27E broadly remain...

Lupin Ltd. is trading below its 200 day SMA of 2025.5

Lupin Ltd.

07 Aug 2025

2007.00

0.13%

Risk towards exclusive products emerging; valuation attractive

Hold: Lupin Ltd.

Recommendation Target

ICICI Securities Limited

Lupin’s Q1FY26 result was largely in-line with our estimates. Launch of Tolvaptan in US (180 days exclusivity) helped Lupin offset the impact of price erosion in its US portfolio and a muted performance in India.

Lupin Ltd. is trading below its 200 day SMA of 2025.5

Lupin Ltd.

07 Aug 2025

2007.00

0.13%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We recommend a BUY rating with a target price of Rs 2,500/share.

Lupin Ltd. is trading above its 150 day SMA of 1980.4

Lupin Ltd.

03 Jul 2025

2007.00

0.13%

Lupin (BUY): Lupin carves out Consumer Healthcare business

Buy: Lupin Ltd.

BOB Capital Markets Ltd.

LPC's OTC carve-out won't significantly impact financials, but aims to double OTC sales by sharpening focus

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

16 May 2025

2007.00

0.13%

Lupin (LPC IN) Q4FY25 Result Update Strong US...

Buy: Lupin Ltd.

Target

Prabhudas Lilladhar

Lupin's (LPC) Q4FY25 EBITDA was at Rs13bn (up 30% YoY) ~10% beat to our estimates on the back of higher US sales supported by niche launches. GMs improved YoY. LPC saw remarkable turnaround in profitability with ~2x jump in EBITDA over FY23-24 aided by better product mix, continued niche launches in the US, clearance from USFDA for facilities, domestic formulations regaining momentum and cost optimization measures. We expect margins to sustain given a strong pipeline in the US. Our FY26E stands increase by 5% as we factor...

Lupin Ltd. is trading below its 200 day SMA of 2025.5

Lupin Ltd.

15 May 2025

2007.00

0.13%

Niche products and superior execution lead to robust 4Q and FY25 performance

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered slightly better-than-expected revenue, EBITDA, and PAT for the quarter (4% beat). LPC continues to track well in the US generics segment (40% of 4Q sales), clocking the highest quarterly run-rate of USD245m over the past 24 quarters.